EPIEN Medical is a privately-held biotechnology company focused on developing a new era of powerful, non-antibiotic agents capable of removing biofilm and microorganisms on contact. The company’s patented HybenX® technology utilizes unique mechanisms unlike any other products found in the marketplace to safely remove a wide variety of microbial biofilms, including MRSA (staph infection).
Products containing HybenX® technology are approved as Class I medical devices in the European Union and Canada. The company currently has products for sale in 23 countries throughout Europe, the Middle East, and Africa, as well as Canada and Australia through contracted distributor relationships. EPIEN also manufactures the drug Debacterol, which is sold to dentists in the United States as a unique treatment for Aphthous ulcers (canker sores).
EPIEN has developed HybenX® technology for a variety of professional dental applications, including a general-purpose focal dental irrigant for the eradication of biofilm inside and outside of the oral cavity. EPIEN’s future activities will focus on the development of products to treat a variety of topical skin infections ranging from ailments such as athlete’s foot to more severe conditions such as diabetic chronic wounds.